It’s Never Too Soon: How and When to Engage Medical Affairs
Engagement with Medical Affairs is critical at every juncture in the drug development process, with Medical Affairs acting as a key liaison between internal stakeholders, a new generation of physicians, and patient advocates...
Read MoreTop Stories
It’s Never Too Soon: How and When to
Engagement with Medical Affairs is critical at every...
Celebrating Health Literacy Month 2024:
October is Health Literacy Month, a reminder of the...
Celebrating World Patient Safety Day 2024:
On World Patient Safety Day 2024, we focus on the critical...
Filter
Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy
Read this update on how the New England Journal of Medicine is trying to promote...
3 Interesting Facts about Plain Language Summaries
Did you know these 3 facts about plain language summaries?...
MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)
An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...
Bringing New Devices to Market under the EU MDR
With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Pharma, Physician, and Patient Pain Points Regarding Clinical Trials
Pharma, physicians, and patients consistently face challenges related to clinical trials. Here's a quick look...
Clinical Trial Summaries – What Are They and Why Do They Matter for Pharma?
A majority of patients feel lay summaries for clinical trials are very important and won’t...